Key result
Low-dose statins yield target LDL-C reduction in only ~29% of post-CABG patients at 1 year.
Why the study?
Patients undergoing CABG require intensive lipid lowering for secondary prevention, yet real-world achievement of guideline-recommended >=50% LDL-C reduction using low-dose statin therapy remains uncertain.
Does low-dose statin therapy (20 mg) achieve a ≥50% reduction in LDL-C over 12 months in patients following coronary artery bypass grafting (CABG)?
Cohort (n=170)
No
Does low-dose statin therapy (20 mg) achieve a ≥50% reduction in LDL-C over 12 months in patients following coronary artery bypass grafting (CABG)?
Low-dose statin therapy (20 mg) following CABG yields progressive LDL-C reductions over one year, but fails to achieve the guideline-recommended ≥50% LDL-C reduction at 3 or 6 months and reaches it in only 28.8% of patients at 12 months, underscoring the need for early monitoring and treatment intensification.
Answers are grounded in this paper and cite their sources.
Low-dose statins were associated with low target LDL-C reduction rates post-CABG; leaves open whether intensification improves outcomes in this population.
Objectives: Patients undergoing coronary artery bypass grafting (CABG) require intensive lipid lowering as part of secondary prevention. However, real-world achievement of guideline-recommended ≥50% LDL-C reduction with low-dose statin therapy remains uncertain. Aim of this study was to determine the proportion of patients achieving ≥50% LDL-C reduction and to assess the magnitude of LDL-C reduction over time among post-CABG patients receiving 20 mg dose of statins. Methodology: This retrospective cohort study included 170 post-CABG patients receiving low-dose statin therapy. LDL-C levels were recorded at baseline and at 3, 6, and 12 months. The primary outcome was the proportion of patients achieving ≥50% LDL-C reduction at each time point. Within-subject changes over time were assessed using the Friedman test, with post-hoc pairwise comparisons conducted using Wilcoxon signed-rank tests with Bonferroni correction. Results: Median LDL-C reduction increased progressively from 16.3% (IQR: 10.7–21.0) at 3 months to 31.0% (IQR: 19.6–35.4) at 6 months and 45.9% (IQR: 25.7–50.6) at 12 months. Differences across time points were statistically significant (Friedman χ² = 423.9, p < 0.001; Kendall’s W = 0.836). No patients achieved ≥50% LDL-C reduction at 3 or 6 months, whereas 28.8% (95% CI: 22.5–36.1) achieved this target at 12 months. Mean LDL-C declined from 152.9 ± 20.6 mg/dL at baseline to 94.7 ± 27.6 mg/dL at 12 months. Conclusion: LDL-C reduction following CABG with low-dose statins is progressive over time; however, achievement of ≥50% reduction is limited within the first year. These findings highlight the need for closer monitoring and potential treatment intensification.
No takes yet. Share an insight, caveat, or question.
Agha et al. (2026) conducted a cohort in Post-coronary artery bypass grafting (CABG) dyslipidemia / secondary cardiovascular prevention (n=170). Low-dose statin therapy (20 mg) was evaluated on Proportion of patients achieving >=50% LDL-C reduction from baseline at 12 months (95% CI 22.5-36.1, p=<0.001). Low-dose statin therapy post-CABG resulted in 0% of patients achieving >=50% LDL-C reduction at 3 and 6 months, and 28.8% at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: